AUGUSTUS 分析:房颤合并 ACS 或 PCI 后抗栓策略对总事件的影响
AUGUSTUS 试验的二次分析评估房颤合并近期 ACS 或 PCI 患者中不同抗栓方案对总出血、缺血事件及住院的影响。结果显示阿哌沙班较 VKA 显著降低总出血风险,阿司匹林较安慰剂显著增加总出血风险,而总缺血事件无显著差异。结论支持阿哌沙班联合低效 P2Y12 抑制剂(氯吡格雷)不加阿司匹林作为标准治疗。
要点
- 阿哌沙班较 VKA 显著降低总出血风险(RR 0.66)。
- 阿司匹林较安慰剂显著增加总出血风险(RR 2.14)。
- 支持阿哌沙班联合氯吡格雷不加阿司匹林作为标准治疗。
核心结论
- 在房颤合并近期 ACS 或 PCI 患者中,阿哌沙班较 VKA 显著降低总出血风险,阿司匹林较安慰剂加倍总出血风险而总缺血事件无显著变化。
- 基于总事件评估,支持阿哌沙班联合低效 P2Y12 抑制剂(氯吡格雷)不加阿司匹林作为该高危人群的标准治疗。
研究设计与样本
- AUGUSTUS 试验的二次分析,该试验为 2×2 析因随机对照试验,评估阿哌沙班 vs VKA 及阿司匹林 vs 安慰剂。
- 纳入房颤合并 ACS 或 PCI 且在接受 P2Y12 抑制剂治疗的患者。
- 分析至少接受 1 剂研究药物的患者的总出血、总缺血事件及总住院情况。
主要发现
- 6 个月随访中,4568 例中 573 例(12.5%)发生至少 1 次出血事件,其中 110 例(19.2%)发生多次出血。
- 4614 例随机参与者中 219 例(4.7%)发生至少 1 次缺血事件,其中 75 例(34.2%)发生多次缺血事件。
- 1125 例(24.4%)发生至少 1 次住院,其中 384 例(34.1%)发生多次住院。
- 阿哌沙班较 VKA 显著降低总出血风险(RR 0.66;95%CI 0.55-0.80),总缺血事件(RR 0.83;95%CI 0.58-1.20)和总住院(RR 0.90;95%CI 0.79-1.03)相似。
- 阿司匹林较安慰剂显著增加总出血风险(RR 2.14;95%CI 1.75-2.60),总缺血事件(RR 0.75;95%CI 0.52-1.08)和总住院(RR 1.11;95%CI 0.97-1.27)相似。
临床怎么用
- 对于房颤合并近期 ACS 或 PCI 且在接受 P2Y12 抑制剂的患者,优先选择阿哌沙班而非 VKA 以降低总出血风险。
- 避免使用阿司匹林,因其加倍总出血风险而无显著缺血获益。
- 支持阿哌沙班联合低效 P2Y12 抑制剂(氯吡格雷)不加阿司匹林作为标准抗栓方案。
局限性
- 为 AUGUSTUS 试验的二次分析,结果属探索性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exist on the optimal antithrombotic strategy to minimize total bleeding and ischemic events for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) and atrial fibrillation (AF). OBJECTIVES: The authors sought to identify the antithrombotic regimen that minimized total major or clinically relevant nonmajor bleeding events, ischemic events, and hospitalizations after ACS or PCI in AF. METHODS: We conducted a secondary analysis of AUGUSTUS (Open-label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), a 2×2 factorial, randomized trial evaluating apixaban vs a vitamin K antagonist (VKA) and aspirin vs placebo in patients with AF and ACS or PCI who were on P2Y12 inhibitor therapy. We determined the incidence of total major or clinically relevant nonmajor bleeding events in patients receiving at least 1 dose of study therapy, total ischemic events, and total hospitalizations among patients randomized to each antithrombotic strategy. RESULTS: Over 6 months of follow-up, 573 of 4,568 (12.5%) patients experienced at least 1 bleeding event while on study drug; among them, 110 (19.2%) had multiple bleeding events. Compared with those with 1 bleeding event, patients with multiple bleeding events were more likely to be on a high-potency P2Y12 inhibitor (prasugrel or ticagrelor vs clopidogrel). Of the 4,614 randomized participants, 219 (4.7%) had at least 1 ischemic event, among whom 75 (34.2%) had multiple ischemic events. At least 1 hospitalization occurred in 1,125 (24.4%) patients; among them, 384 (34.1%) had multiple hospitalizations. Apixaban, compared with VKA, significantly reduced the risk of total bleeding (rate ratio [RR]: 0.66; 95% CI: 0.55-0.80). Apixaban had similar rates of total ischemic events (RR: 0.83; 95% CI: 0.58-1.20) and total hospitalizations (RR: 0.90; 95% CI: 0.79-1.03) compared with VKA. Aspirin, compared with placebo, significantly increased the risk of total bleeding (RR: 2.14; 95% CI: 1.75-2.60). The rates of total ischemic events (RR: 0.75; 95% CI: 0.52-1.08) and total hospitalizations (RR: 1.11; 95% CI: 0.97-1.27) with aspirin and placebo were similar. CONCLUSIONS: Among patients with AF and recent ACS or PCI, apixaban significantly reduced total bleeding risk compared with VKA. Aspirin doubled total bleeding risk compared with placebo without a significant change in total ischemic events. Based on this assessment of total events, our findings support the use of apixaban plus a low-potency P2Y12 inhibitor (ie, clopidogrel) without aspirin as the standard therapy for this high-risk patient population. (A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis [Blood Clots] Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart; NCT02415400).
引用
- Tannu, Lopes, Wojdyla, et al. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025. PMID: 39918467. doi:10.1016/j.jacc.2024.10.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。